Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LETRODON: Letrozole in Oocyte Donors
NCT06244745Phase 3Recruiting
- Sponsor
- International Vaccine Institute
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of letrozole in ovarian hyperstimulation syndrome (OHSS), sponsored by International Vaccine Institute. Started Dec 2023; status: recruiting.
02
Drugs
letrozole
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT06244745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06244745.